Relay Therapeutics (RLAY) Operating Leases (2019 - 2026)

Relay Therapeutics (RLAY) has reported Operating Leases for 8 consecutive years, with $27.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 32.87% year-over-year to $27.7 million; the TTM figure through Mar 2026 stood at $27.7 million (down 32.87% YoY), while the FY2025 annual figure was $28.7 million, down 32.92% from the prior year.
• Operating Leases retreated to $27.7 million in Q1 2026 per RLAY's latest filing, from $28.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $54.6 million in Q3 2022 and bottomed at $20.0 million in Q2 2022.
• Historically, Operating Leases has averaged $40.5 million across 5 years, with a median of $44.3 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases jumped 155.25% — and 2025, when it plunged 33.01%.
• Relay Therapeutics' Operating Leases stood at $53.5 million in 2022, then fell by 9.28% to $48.5 million in 2023, then slipped by 11.81% to $42.8 million in 2024, then plunged by 32.92% to $28.7 million in 2025, then decreased by 3.53% to $27.7 million in 2026.
• Business Quant data shows RLAY's Operating Leases at $27.7 million in Q1 2026, $28.7 million in Q4 2025, and $29.7 million in Q3 2025.